Sen. Frist's Diagnosis On DTC: GAO Report, Two-Year Moratorium For New Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Majority Leader Frist requests Government Accountability Office examine FDA's oversight of direct-to-consumer ads and their impact on drug usage and costs. The senator also requests drug companies voluntarily restrict DTC ads during the first two years a product is on the market.
You may also be interested in...
Pharma DTC Spend Increasing At Twice The Rate Of Physician Promotions, GAO Finds
A Government Accountability Office report, released Dec. 14, calls for improvements in FDA’s oversight of direct-to-consumer advertising.
Pharma DTC Spend Increasing At Twice The Rate Of Physician Promotions, GAO Finds
A Government Accountability Office report, released Dec. 14, calls for improvements in FDA’s oversight of direct-to-consumer advertising.
DTC Advertising Does Not Elicit Patient Requests For Prescriptions, Study Says
The study “challenges many of the assumptions of both academic and public policy critics of DTC,” CommonHealth concludes.